Combined effects of targeted blood pressure, oxygenation, and duration of device-based fever prevention after out-of-hospital cardiac arrest on 1-year survival: post hoc analysis of a randomized controlled trial.

"Declarations Ethics approval and consent to participateEthical approval was obtained prior to trial initiation from the regional ethics committee of The Capital Region of Denmark (Approval H-16033436). In accordance with Danish legislation, trial inclusion of incapacitated subjects in the acute setting was performed with consent from a trial guardian, and as soon as possible consent from a relative. Patients regaining consciousness were also consented. Consent for publicationNot applicable. Competing interestsAM has outside of submitted work been employed by Novo Nordisk since May of 2020. Competing interests AM has outside of submitted work been employed by Novo Nordisk since May of 2020."

"Funding Open access funding provided by Copenhagen University. The BOX trial was supported by an unrestricted research grant from the Novo Nordisk Foundation (NNF17OC0028706), and Professor Christian Hassager was supported by an unrestricted research grant from the Lundbeck Foundation (R186-2015-2132)."

"Trial registration ClinicalTrials.gov NCT03141099, Registered 30 April 2017."